Clinical Trials Logo
  1. Home
  2. Corneal Neovascularization
  3. NCT00515684
  4. Details
NCT00515684 Clinical Trial

Corneal Thinning During Topical Bevacizumab Therapy

Corneal Neovascularization Clinical Trial

Clinical Trial Details — Status: Withdrawn

Administrative data
NCT number NCT00515684
Other study ID # 4-2006-0234
Secondary ID
Status Withdrawn
Phase N/A
First received August 13, 2007
Last updated April 29, 2015
Start date May 2007
Est. completion date December 2008

Study information
Verified date April 2015
Source Yonsei University
Contact n/a
Is FDA regulated No
Health authority Korea: Institutional Review Board
Study type Interventional

Clinical Trial Summary

The purpose of this study is to determine whether topical bevacizumab is safe or not when used in corneal neovascularization for long term period.

Recruitment information / eligibility
Status Withdrawn
Enrollment 0
Est. completion date December 2008
Est. primary completion date December 2008
Accepts healthy volunteers
Gender Both
Age group N/A and older
Eligibility Inclusion Criteria:

- clinical diagnosis of corneal neovascularization

- must be able to apply eyedrop

Exclusion Criteria:

- have active keratitis

Study Design

Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science

Related Conditions & MeSH terms

Intervention

Drug:
• bevacizumab (Avastin)

Locations
Country Name City State
Korea, Republic of Severance hospital Seoul

Sponsors (1)
Lead Sponsor Collaborator
Yonsei University

Country where clinical trial is conducted

Korea, Republic of, 

See also
  Status Clinical Trial Phase
Completed NCT00555594 - Prospective Study to Determine the Effect of Subconjunctival Bevacizumab (AVASTIN) in Corneal Neovascularization Phase 2/Phase 3
Completed NCT00004430 - Randomized Study of Photodynamic Therapy Using Dihematoporphyrin in Patients With Corneal Neovascularization N/A
Completed NCT00769145 - Ranibizumab for the Inhibition of Neovascularization in the Cornea Following Corneal Transplant Surgery Phase 1
Completed NCT01257750 - Treatment of Corneal Neovascularization With Topical Pazopanib Phase 1/Phase 2
Recruiting NCT04787471 - Corneal Crosslinking for Treatment of Corneal Neovascularization Phase 2/Phase 3
Not yet recruiting NCT06412718 - Validation of Human Drugs Target of Repurposed Drugs and Novel Therapies
Active, not recruiting NCT00992849 - Bevacizumab for the Treatment of Corneal Neovascularization Phase 2
Terminated NCT02797704 - Subconjunctival Aflibercept (EYLEA®) for the Treatment of Corneal Neovascularization Phase 1/Phase 2
Terminated NCT01868360 - Using Aflibercept Injection to Treat Blood Vessel Growth Over the Cornea Phase 1
Withdrawn NCT02042027 - Subconjunctival IVIg (Gamunex-C) Injection for Corneal Neovascularization and Inflammatory Conditions Phase 1
Recruiting NCT04215393 - An Exploratory Clinical Trial Evaluating the Tolerability and Efficacy of KH906 in Patients With Corneal Neovascularization Phase 1
Completed NCT00797303 - The Effect of Bevacizumab on Corneal Neovascularization Phase 4
Recruiting NCT05659940 - Correlation Between a Novel Subset of Neutrophil and Corneal Neovascularization.
Completed NCT00559936 - Topical Avastin for Treatment of Corneal Neovascularization Phase 1
Completed NCT01072357 - Safety and Efficacy of Bevacizumab in High-Risk Corneal Transplant Survival Phase 1/Phase 2
Recruiting NCT04620109 - Clinical Evaluation of Safety and Tolerability of KDR2-2 Eye Drops in Healthy Volunteers With Pharmacokinetic Assessment Phase 1
Completed NCT00512876 - Effectiveness and Safety of Topical Bevacizumab (Avastin) for Treatment of Corneal Neovascularization N/A
Recruiting NCT05011916 - The Safety and Efficacy of KDR2-2 Suspension Eye Drops in the Treatment of Corneal Neovascularization Phase 1/Phase 2
Completed NCT01996826 - A Multi-Center Study of the Safety and Efficacy of Bevacizumab in High-Risk Corneal Transplant Survival Phase 1/Phase 2
Terminated NCT00915590 - Topical IL-1-Ra for Treatment of Corneal Neovascularization Phase 1/Phase 2